News

Euclid Vision Announces Acquisition of Visionary Optics

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost exclusively on scleral contact lenses. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.

“We are excited about joining forces with Visionary Optics. This union opens exciting opportunities for cross-company collaboration and innovation,” said Joseph Boorady, Euclid President and CEO. “Visionary Optics, with its best-in-class scleral lens innovations and world class customer service, is a great match for the Euclid portfolio. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses — positions us to better serve our customers and their patients.”

Euclid and Visionary Optics share many of the same cultural values, such as a dedication to professional education, strong partnerships with eye care professionals, and market savvy product innovation. Each company will retain their unique individual brand, while being perfectly positioned to reap the benefits of shared future endeavors.

“This is an incredible opportunity for Visionary Optics to work with a partner who can help take our business and technology to the next level, while also maintaining the key foundational aspects of what has fueled our success including our customer-driven corporate culture and high-tech research orientation,” said Donald Sanders, MD, PhD Visionary Optics President and CEO.

Euclid and Visionary Optics understand that clinicians partner with companies that not only offer unparalleled lens design and the highest-level of advanced manufacturing, but those that also provide exceptional customer service. “Expert customer service is critical to the success of the clinicians who work with us, and we pride ourselves on the level of expertise for which our customer service team is known,” said Dr. Sanders. “As we unite with Euclid, preserving these team values are integral to maintaining our role as a leader in scleral lens design and distribution. Thus, our customers can count on the same great service they are used to with Visionary Optics.”

Recent News

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan

10/20/2025

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to